

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Swan et al.

10/723,505

Serial No.:

November 26, 2003

Filed: For:

BIOCOMPATIBLE POLY-

MERIZATION ACCELERATORS

Examiner:

Naff, David M.

Group Art Unit:

1657

Docket No.:

SRM0006/US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 I CERTIFY THAT ON UWU 4,2004, THIS PAPER IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

JONI/LUREK

DECLARATION UNDER 37 C.F.R. § 1.131

Dear Sir:

- I, Dale G. Swan, declare the following:
- 1. I am an applicant of the above-identified patent application.
- 2. I have worked for SurModics as a research chemist for 21 years; SurModics is the current assignee of the above-identified patent application. I am paid a salary and other compensation for my work for SurModics.
- I have at least 16 years of experience in developing chemical reagents for use in the body, including reagents for use in polymeric systems for regenerative and drug delivery technologies. I hold a master's degree in organic chemistry, which was awarded from the University of Minnesota in 1970.
- 4. The invention claimed in the above-identified application was conceived and reduced to practice in the United States of America prior to October, 2002, as indicated by the following facts, supported by attached Exhibits 1-13.

Applicant: Swan et al. Serial No.: 10/723,505 File: November 26, 2003

For: BIOCOMPATIBLE POLYMERIZATION ACCELERATORS

Examiner: Naff, David M. Group Art Unit: 1657 Docket No.: SRM0006/US

- 5. All of the work described in Exhibits 1-13 was performed at SurModics, Eden Prairie, Minnesota, U.S.A., prior to October 2002.
- 6. Exhibits 1-13 include proposals, synthetic schemes, and experimental data describing the preparation of polymerization accelerators having biocompatible functional groups, and the use of these accelerators for preparing biocompatible polymeric matrices, which can be formed in the presence of tissue or cells. The accelerators described in these Exhibits include ones having an N-vinyl amide functionality and a sulfonate functionality.
- 7. Exhibits 1 and 2 consist of pages 20 and 26, respectively, from my notebook #2683 which were dated and signed prior to October 2002, and which describe a scheme for the synthesis of the biocompatible polymerization accelerator N-vinylsuccinimide-2-sulfonate (NVSS). NVSS has N-vinyl amide and sulfonate functionalities and is specifically described in the above-identified patent application at pages 29-30 (Example 4, compound 4). NVSS falls under the scope of the accelerator recited in claims of the patent application.
- 8. Exhibits 3-10 consist of pages 21, 26, 27, 30, 31, 37, 39, and 39 (cont.) respectively, from my technical assistant's notebook #2706 which were dated and signed prior to October 2002, and which describe the details of the laboratory synthesis of NVSS.
- 9. Exhibit 11 consists of page 30 from my notebook #2683 which were dated and signed prior to October 2002, and which describe a scheme for the synthesis of the biocompatible polymerization accelerator potassium 3-({3-[formyl(vinyl)amino] propanoyl}oxy)propane-1-sulfonate (NVF-SPA), as well as the details of its laboratory synthesis. NVF-SPA has N-vinyl amide and sulfonate functionalities and is specifically described in the above-identified patent application at page 30 (Example 5, compound 5). NVF-SPA falls under the scope of the accelerator recited in claims of the patent application.

Applicant: Swan et al. Serial No.: 10/723,505 File: November 26, 2003

For: BIOCOMPATIBLE POLYMERIZATION ACCELERATORS

Examiner: Naff, David M. Group Art Unit: 1657 Docket No.: SRM0006/US

- 10. Exhibit 12 consists of a SurModics Intellectual Property and Proprietary Product Idea Form (the SurModics IP Form) that was dated and signed prior to October 2002. The SurModics IP Form describes the synthesis of biocompatible polymerization accelerators, including ones having N-vinyl amide and sulfonate functionalities. The SurModics IP Form also describes the use of biocompatible polymerization accelerators for preparing protective hydrogel coatings around cells.
- 11. Exhibit 13 consists of page 79 from my technical assistant's notebook which was dated and signed prior to October 2002, which describes compositions that include the polymerizable material hyaluronic acid macromer and the polymerization accelerator NVSS. This composition falls under the scope of the composition recited in claims of the patent application, and is described in the above-identified patent application at page 32 (Example 9). The composition was polymerized to form a biocompatible polymeric matrix, which can also be formed in the presence of tissue or cells.
- 12. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements have been made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or patent issuing thereon.

Jane 2, 2009 Dale G. Swan

On this day of <u>une</u>, 2009, before me personally appeared Dale G. Swan, to me known to be the person described in and who executed the foregoing instrument and acknowledged that he executed the same as her free act and deed.

Notary Public

#49537v5

PATRICIA M. BEST
Notary Public
Minnesota
My Commission Expires January 31, 2010

Exhibit 1




Exhibit 2

Witnessed & Understood by me, Date Invented by Catellicity

Dal law Recorded by P. Catellicity

Exhibit 3

The state of the s	Section of the sectio
From Page No.	
N-Vinye Maleimi	de 2706-21. In NAR tube, but using
1	+ Nauso3 - HC-C-N so3Na.
50 mig 0,400 ninos	104.06 225.15 50.8 mg 91.41 mg & 0.488 muele 0.406 manche
in lime bao No	poère solution 50 mez N-Vinge Mallemide
I add solution land solution almoust all we pipel filter t	be was placed 50 mis N-Vinyl Maletung of 516mis Nulleon in 19 ml 520. I at 500c water booth for 10 min, es dissolved, filter off therough o another NMP tube & submit
Results see Rx at RT wo	p. 25 back side. Up slow.
Rx#2 18 N-1002 g	ling Maleinide 2706-21 + solution NOCHEO2 in 20 ml Di-H20 (0.0098 M) 550c from 4 p.m. over weekend.
fletered of I water was removed with 2 × 20 mil cheez (at 60° c under water apprivator). Got 171 g. yellowish route (2706-26-1) or 934% from	
Prepatre 30 mg/0,7m L 520 for NAR (see p. 26 Back dide)	
Witnessed & Understood by me,	Date invented by a 20
X \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	

Exhibit 4

Exhibit 5


back siglet. 30 mg/0.75 ml bao for NMR /see p.29 Product looks good by NMR.


1.C was developed in CH304/CMCR3=1/99/see p.298)

CH304/CHCR3=10/90. one spot. To Page No. 22

Wilnessed & Understood by me. Date transented by Wal Swan

Exhibit 6





Erom p. 39.

solids (2706-39-8). Seems that product started to polymerize.

Pedisolve solid (39-3) in as me chees by chas on an Orbit Shafer for 20 min, filter off solids that didn't dissolve.

Remove CHCf3 on a Rotorap at PT under water aspirator, with air blooding into a flator of solvent were removed by sweeping on with air, to gave 1.41 9. yellow solid




Exhibit 10




Exhibit 11

SurModics Intellectual Property and Proprietary Product Idea Form Originator(s) Date Ron Ofstead and Dale Swan Title/Key Words N-vinylamides as accelerators in matrix formation Reference (Personal Notes/Notebook Number and Pages) 2683-16,20,26 **Brief Description** Cells can be covered with a protective hydrogel coating. The polymerization of PBG-triacrylate around the cells is accelerated by the addition of N-vinylamides. In addition the presence of sulfonate containing monomers (ie AMPS) have been useful in improving biocompatibility. The idea was to synthesize reagents containing N-vinylamides and sulfonate functionality. The attachment of figures 1 to 4 show the reactions used to make N-vinyl amides. Advantages and Features The materials proposed can be made in one or two steps from available materials. Preliminary tests indicated firm gels resulted from the cyclic products synthesized. Reduced to Practice (Date/Notebook Number and Pages) 2706-21, 26, 30, 31, 37, 39 from Originator(s) Date

Printed Name

Jerome

Printed Name

PROPRIETARY SurModics, Inc.

Originator(s)

Witness

Date

Date

Date

Exhibit 12

Signature

theseed & Understood by me, Date Invented by Date